Evidence map›Paper›PMID 36640129›Full record

Trial reportThe Journal of antimicrobial chemotherapy2023

Plasma concentration of orally administered amoxicillin and clindamycin in patients receiving haemodialysis.

Camilla N Solli, Magnus Bock, Kamal P Kaur, Jonas H Kristensen, Eva Greibe, Henrik P Hansen, Lene Boesby, Rikke Borg, Mavish Chaudry, Elke Hoffmann-Lücke and 8 more

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The Journal of antimicrobial chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Camilla N SolliDepartment of Cardiology, Zealand University Hospital, Sygehusvej 10, Roskilde 4000, Denmark.ORCID 0000-0002-7514-9083
Magnus BockDepartment of Clinical Microbiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
Kamal P KaurDepartment of Cardiology, Zealand University Hospital, Sygehusvej 10, Roskilde 4000, Denmark.
Jonas H KristensenDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Eva GreibeDepartment of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.
Henrik P HansenDepartment of Nephrology, Copenhagen University Hospital-Herlev-Gentofte, Herlev, Denmark.
Lene BoesbyDepartment of Medicine, Zealand University Hospital, Roskilde, Denmark.
Rikke BorgDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Mavish ChaudryDepartment of Cardiology, Copenhagen University Hospital-North Zealand, Hilleroed, Denmark.
Elke Hoffmann-LückeDepartment of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.
Claus MoserDepartment of Clinical Microbiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0002-7664-8570
Alexander C FalkentoftDepartment of Cardiology, Zealand University Hospital, Sygehusvej 10, Roskilde 4000, Denmark.
Emil FosbølDepartment of Cardiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0002-2048-4167
Lauge ØstergaardDepartment of Cardiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0003-3298-1467
Christian Torp-PedersenDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Henning BundgaardDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-0563-7049
Kasper IversenDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0003-0504-8487
Niels E BruunDepartment of Cardiology, Zealand University Hospital, Sygehusvej 10, Roskilde 4000, Denmark.
University of Copenhagen · DKCopenhagen University Hospital · DKAarhus University Hospital · DKGentofte Hospital · DKZealand University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesIn the randomized controlled trial PANTHEM, the prophylactic effect of oral amoxicillin or clindamycin is investigated in patients receiving chronic haemodialysis (HD). However, data on plasma concentrations of these antibiotics during HD are sparse. This study aims to determine if the plasma concentration of amoxicillin and clindamycin is sufficient during HD after oral administration of amoxicillin and clindamycin at three different time intervals prior to the HD procedure.

methodsAdult patients receiving chronic HD were investigated twice with an interval of at least 7 days starting with either a tablet of 500/125 mg amoxicillin/clavulanic acid or a tablet of 600 mg clindamycin. Patients were randomized to take the antibiotics either 30, 60 or 120 min prior to the HD procedure. Plasma antibiotic concentrations were measured at start, midway and at the end of HD. A lower threshold was set at 2.0 mg/L for amoxicillin and at 1.0 mg/L for clindamycin. In addition, a population pharmacokinetic (PK) analysis was performed, assessing PTA.

resultsIn the amoxicillin cohort (n = 37), 84% of patients and 95% of all plasma amoxicillin concentrations were above or at the threshold throughout the dialysis procedure. In the clindamycin cohort (n = 33), all concentrations were above the threshold throughout the dialysis procedure. Further, in all patients, the mean plasma concentration of both amoxicillin and clindamycin across the HD period was well above the threshold. Finally, the PK model predicted a high PTA in the majority of patients. DISCUSSION: In patients on chronic HD, oral administration of amoxicillin/clavulanic acid (500/125 mg) or clindamycin (600 mg) within 30-120 min prior to HD leads to a sufficient prophylactic plasma concentration across the HD period.

Indexed as

AmoxicillinClindamycinAdultAmoxicillin-Potassium Clavulanate CombinationAnti-Bacterial AgentsHumansRenal DialysisAmoxicillinAmoxicillin-Potassium Clavulanate CombinationAnti-Bacterial AgentsClindamycin

Identifiers

PMID36640129
PMCPMC9978593
OpenAlexW4316114647

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.